Polymorphisms of MAMLD1 gene in hypospadias

PURPOSE

Mastermind-like domain containing 1 (MAMLD1) is a causative gene for the fetal development of male external genitalia. Almost 10% of patients with both severe and non-severe hypospadias exhibit mutations of MAMLD1. The aim of this work was to determine whether polymorphisms of MAMLD1 are a genetic risk factor for hypospadias.

MATERIAL AND METHODS

This study included 150 hypospadias with a range of severities and 150 controls. Direct sequencing of the MAMLD1 coding exons and their flanking splice sites was performed. In silico secondary and tertiary structure prediction and accessibility of changed amino acids were evaluated using JPred, Netsurf and PHYRE software. Functional studies of the transactivation of haplotypes on Hes3 promoter were performed in vitro using cDNAs of missense variants of MAMLD1.

RESULTS

The p.P286S polymorphism was identified in 17/150 patients and 12/150 controls (11.3% vs. 8.0%, p = 0.32). The p.N589S polymorphism was identified in 22/150 patients and 12/150 controls (14.6% vs. 8.0%, p = 0.068). The double polymorphism (S-S haplotype) was present in 16/150 patients and 6/150 controls (10.6% vs. 4.0%, p = 0.044, OR = 2.87, CI from 1.09 to 7.55). The association of polymorphisms consistently revealed a modification in the structure prediction or amino acid accessibility in all three in silico models. The P286S, N589S and P286S + N589S proteins did not exhibit reduced transactivating activity on Hes3 promoter.

CONCLUSION

Polymorphisms of MAMLD1 gene are frequent in patients with hypospadias. Although no change in transactivation was noted on Hes3 promoter, the in silico studies and the significantly increased incidence of the S-S haplotype in hypospadiac patients raise the hypothesis of a particular susceptibility conferred by these variants.

[Giant hamartoma of the lung]

Hamartomas are the most common benign tumors of the lungs and usually present as solitary intraparenchymal lesions a few centimeters in diameter which are detected radiologically as an incidental finding. This article reports on a case of a giant pulmonary hamartochondroma 29 cm in diameter, which impressed preoperatively and intraoperatively as an extrapulmonary neoplasm. The detection of smaller mesenchymal neoplastic lesions in the lungs and pleura is a further special feature of this case.

[Clinical symptoms, treatment and outcome of EHEC and EHEC-HUS patients treated as in-patients]

BACKGROUND AND OBJECTIVE

From May to June 2011 an outbreak of Shiga-toxin-producing Escherichia coli (EHEC) infections occurred in northern Germany leading to a great number of patients with hemolytic-uremic syndrome (HUS). A monocentric case series from Hamburg is described.

MATERIAL AND METHODS

All patients at that time presenting with acute diarrhoea at the Asklepios Clinic Barmbek in Hamburg were proved for EHEC infections. Clinical data of EHEC and EHEC-HUS patients treated as in-patients as well as stool analysis and laboratory results were documented.

RESULTS

In total, 117 patients suspicious to have EHEC infection were treated as in-patients. In 68 patients an EHEC infection (n = 36) or HUS (n = 32) could be confirmed. Additional infections with other diarrhoea-causative organism could be revealed in 23 of these 68 patients (34 %). The median age of the HUS patients was 44 years being significantly lower compared to the age of EHEC patients without HUS (51 years, p = 0,04). In the group of HUS patients there were significantly more women (26/32 vs. 21/36, p = 0.03). 19 patients with HUS dialysis was necessary. In total, a number of 248 plasma separations were required. 18 patients developed severe neuro-psychiatric symptoms. One patient died.

CONCLUSION

This monocentric case series describes one of the so far largest published series of mostly young and female patients with EHEC and EHEC-HUS.

Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome

OBJECTIVE

Adult height deficit seen in Turner syndrome (TS) originates, in part, from growth retardation in utero and throughout the first 3 years of life. Earlier diagnosis enables earlier therapeutic intervention, such as with recombinant human GH (r-hGH), which may help to prevent growth retardation. In this open-label, multicentre phase III study, we investigated efficacy and safety in r-hGH treatment in young girls with TS.

SUBJECTS AND METHODS

Girls (n=61) aged <4 years with TS receiving 0.035-0.05 mg/kg per day r-hGH for 4 years were compared with an historical control group (n=51) comprising untreated, age- and height-matched girls with TS. The main outcome measure was change in height SDS (H-SDS). Other measures included changes in height velocity SDS, IGF1 levels and glucose metabolism.

RESULTS

After 4 years, a gain in mean H-SDS of 1.0 SDS (from -2.33±0.73 to -1.35±0.86 SDS) was observed with r-hGH treatment, in contrast to the decrease in mean H-SDS of 0.3 SDS in the control group (from -2.09±0.81 to -2.44±0.73 SDS; P<0.0001). r-hGH treatment was the main predictor of H-SDS gain and accounted for 52% of variability (multivariate analysis). r-hGH was well tolerated. As expected, IGF1 levels rose with treatment. A case of transient glucose intolerance resolved after dietary adaptation.

CONCLUSION

Early treatment with r-hGH helps to prevent natural evolution towards short stature in most girls with TS. IGF1 levels and glucose metabolism should be monitored routinely during r-hGH therapy.

Prognostic factors in allo-SCT of elderly patients with AML

The prognosis of elderly patients with AML after chemotherapy is poor. Allo-SCT is feasible in these patients, but data on prognostic factors and outcome are limited. We analyzed all 102 AML patients ≥55 years, who underwent allo-SCT at our institution from 1997 to 2008. OS and relapse-free survival (RFS) rates at 3 years are 39 and 37%, respectively. Multivariate analysis for OS revealed age ≥60 years and active (refractory or untreated before allo-SCT) or advanced (>CR1) disease as adverse prognostic factors. Patients transplanted in CR1 had a 3-year OS of 67 vs 27% for patients with active/advanced disease. Multivariate analysis for RFS revealed active/advanced disease as the only adverse factor. Patients transplanted in CR1 had a 3-year RFS of 70 vs 22% for patients with active/advanced disease. In all, 17% of patients suffered from acute GVHD ≥grade II. The risk for severe acute GVHD was increased after allo-SCT from mismatched donors. Nonrelapse mortality (NRM) was 23% at 1 year. The only risk factor for NRM was active/advanced disease. In conclusion, allo-SCT from related or unrelated donors yields very good results in elderly AML patients transplanted in CR1. Disease status at transplantation is the most important prognostic factor for transplantation success.

Parameter identification, experimental design and model falsification for biological network models using semidefinite programming

One of the most challenging tasks in systems biology is parameter identification from experimental data. In particular, if the available data are noisy, the resulting parameter uncertainty can be huge and should be quantified. In this work, a set-based approach for parameter identification in discrete time models of biochemical reaction networks from time series data is developed. The basic idea is to determine an outer approximation to the set of parameters for which trajectories are consistent with the available data. In order to approximate the set of consistent parameters (SCP) a feasibility problem is derived. This feasibility problem is used to verify that complete parameter sets cannot contain consistent parameters. This method is very appealing because instead of checking a finite number of distinct points, complete sets are analysed. With this approach, model falsification simply corresponds to showing that the SCP is empty. Besides parameter identification, a novel set-based method for experimental design is presented. This method yields reliable predictions on the information content of future measurements also for the case of very limited a priori knowledge and uncertain inputs. The properties of the method are presented using a discrete time model of the MAP kinase cascade.

Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis

Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80%, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30% increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50% increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.

Parameter identification, experimental design and model falsification for biological network models using semidefinite programming

One of the most challenging tasks in systems biology is parameter identification from experimental data. In particular, if the available data are noisy, the resulting parameter uncertainty can be huge and should be quantified. In this work, a set-based approach for parameter identification in discrete time models of biochemical reaction networks from time series data is developed. The basic idea is to determine an outer approximation to the set of parameters for which trajectories are consistent with the available data. In order to approximate the set of consistent parameters (SCP) a feasibility problem is derived. This feasibility problem is used to verify that complete parameter sets cannot contain consistent parameters. This method is very appealing because instead of checking a finite number of distinct points, complete sets are analysed. With this approach, model falsification simply corresponds to showing that the SCP is empty. Besides parameter identification, a novel set-based method for experimental design is presented. This method yields reliable predictions on the information content of future measurements also for the case of very limited a priori knowledge and uncertain inputs. The properties of the method are presented using a discrete time model of the MAP kinase cascade.

Structure solution with PATSEE

Patterson search is a powerful tool for solving difficult crystal structures since it actively uses chemical information. Our program PATSEE, which attempts to combine the merits of Patterson and direct methods in order to locate a fragment with known geometry in the unit cell, has solved a large number of crystal structures during the last decade and proved to be reliable and widely applicable. We have tested PATSEE successfully on 20 structures of different size and complexity contained in a test data bank using fragments either taken from related crystal structures or calculated by force-field methods. Even structures with several torsional degrees of freedom (like those of oligopeptides) could be solved convincingly. As a result, general experiences – such as requirements for the minimum size and the accuracy of a search fragment, the reliability of the various figures of merit, the chances to locate single atoms and to tackle larger structures – were gained, which should help in finding an optimum strategy for the solution of problem structures with PATSEE.

GARP: a key receptor controlling FOXP3 in human regulatory T cells

Recent evidence suggests that regulatory pathways might control sustained high levels of FOXP3 in regulatory CD4(+)CD25(hi) T (T(reg)) cells. Based on transcriptional profiling of ex vivo activated T(reg) and helper CD4(+)CD25(-) T (T(h)) cells we have identified GARP (glycoprotein-A repetitions predominant), LGALS3 (lectin, galactoside-binding, soluble, 3) and LGMN (legumain) as novel genes implicated in human T(reg) cell function, which are induced upon T-cell receptor stimulation. Retroviral overexpression of GARP in antigen-specific T(h) cells leads to an efficient and stable re-programming of an effector T cell towards a regulatory T cell, which involves up-regulation of FOXP3, LGALS3, LGMN and other T(reg)-associated markers. In contrast, overexpression of LGALS3 and LGMN enhance FOXP3 and GARP expression, but only partially induced a regulatory phenotype. Lentiviral down-regulation of GARP in T(reg) cells significantly impaired the suppressor function and was associated with down-regulation of FOXP3. Moreover, down-regulation of FOXP3 resulted in similar phenotypic changes and down-regulation of GARP. This provides compelling evidence for a GARP-FOXP3 positive feedback loop and provides a rational molecular basis for the known difference between natural and transforming growth factor-beta induced T(reg) cells as we show here that the latter do not up-regulate GARP. In summary, we have identified GARP as a key receptor controlling FOXP3 in T(reg) cells following T-cell activation in a positive feedback loop assisted by LGALS3 and LGMN, which represents a promising new system for the therapeutic manipulation of T cells in human disease.